Standard BioTools, Treeline merge in deal backed by $900 million

Standard BioTools Inc. filed a registration statement for its all-stock merger with Treeline Biosciences, creating a combined entity with over $900 million in cash and an 84% response rate from Treeline's lead lymphoma drug candidate.

"Strengthening our cash position through this transaction with Standard BioTools will help us accelerate the development of our clinical programs," said Josh Bilenker, co-founder and chief executive officer of Treeline.

The merger, expected to close in the second half of 2026, will see the combined company operate as Treeline Biosciences Holdings Inc. and trade on Nasdaq under the ticker TRLN. Treeline previously raised approximately $1.2 billion from a syndicate of leading life sciences investors. The pro-forma cash of more than $900 million is expected to fund operations into 2029.

The deal provides Treeline the financial runway to advance a pipeline spanning oncology, neurology and immunology, with interim data readouts for both TLN-121 and the pan-KRAS inhibitor TLN-372 planned for 2027.

Treeline's lead candidate, TLN-121, is an oral protein degrader of BCL6, a transcriptional repressor critical to germinal center biology. Most diffuse large B-cell, follicular and T follicular helper peripheral T-cell lymphomas depend on BCL6 for growth and survival. Across efficacy-evaluable patients with relapsed or refractory disease, the blended overall response rate reached 84% (n=16/19) with a complete response rate of 32% (n=6/19) by Lugano criteria. Complete responses were observed across all three histologies. Patients had received two to eight prior lines of therapy, with 50% of DLBCL and FL patients having received a prior T-cell or immune-cell engager and 33% having received prior CAR-T therapy. No dose-limiting toxicities were reported, and most treatment-related adverse events were Grade 1.

The registration statement filed with the SEC also details Treeline's broader pipeline, including TLN-254 (EZH2 inhibitor), TLN-372 (pan-KRAS inhibitor) and TLN-499 (BCL-XL degrader). The company plans to evaluate TLN-121 in expansion cohorts both as a monotherapy and in combination with other anti-lymphoma agents. Treeline also expects to begin clinical trials for targeted therapy antibody-drug conjugates and previously unliganded targets.

Sue Desmond-Hellmann, former chief executive officer of the Bill & Melinda Gates Foundation and former chief medical officer at Genentech, joined Treeline's board of directors. "It is striking how much Treeline has accomplished in just five years," she said. During her 14-year career at Genentech, she brought numerous new medicines through development and approval.

Michael Egholm, president and chief executive officer of Standard BioTools, said the transaction milestone brings the company closer to offering stockholders "the unique opportunity to participate in Treeline's future growth prospects." Standard BioTools also plans to pursue potential dispositions of its Mass Cytometry and Microfluidics businesses.

This article is for informational purposes only and does not constitute investment advice.